openPR Logo
Press release

Desmoid Tumors Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Pfizer, Novartis, SpringWorks Therapeutics, Ayala Pharmaceuticals, Iterion Therapeutics, Aadi Bioscience

04-10-2024 07:47 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Desmoid Tumors Market Report 2032: Epidemiology Data, Pipeline

DelveInsight's "Desmoid Tumors Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Desmoid Tumors, historical and forecasted epidemiology as well as the Desmoid Tumors market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Desmoid Tumors market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Desmoid Tumors Market Forecast
https://www.delveinsight.com/sample-request/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Desmoid Tumors Market Report:
• The Desmoid Tumors market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Approximately 65% of the diagnosed cases are either stable or being actively monitored for spontaneous regression. About 9,000 cases in the US will either be stable in 2022 or will be actively monitored for spontaneous regression
• In 2022, there were approximately 14,000 reported cases of Desmoid Tumors in the US, with projections indicating a gradual increase by 2032 at a moderate compound annual growth rate (CAGR). According to DelveInsight's analysis, among the seven major markets (7MM), the United States recorded the highest prevalence of Desmoid Tumors.
• DelveInsight's analysis reveals that the United States accounted for approximately 90% of diagnosed prevalent cases, totaling around 13,000 cases in 2022.
• Less than 3% of all soft-tissue tumours are desmoid tumours, according to the American Society of Clinical Oncology (ASCO). In the United States, 900 to 1,500 persons are given a desmoid tumour diagnosis each year. Although it can happen at any age, this form of tumour primarily affects persons between the ages of 15 and 60
• Desmoid tumours are linked to CTNNB1 mutations in more than 75% of cases, according to a study by Kumar et al. published in 2021 and titled "Desmoid tumour and molecular testing from patient reported data in an international natural history study."
• Key Desmoid Tumors Companies: Pfizer, Novartis, SpringWorks Therapeutics, Ayala Pharmaceuticals, Iterion Therapeutics, Aadi Bioscience, Inc., INSYS Therapeutics Inc, Recursion Pharmaceuticals Inc., and others
• Key Desmoid Tumors Therapies: Sirolimus, Imatinib, Nirogacestat, AL102, Tegavivint, Nab-Rapamycin, Fentanyl sublingual spray, REC-4881, and others
• The Desmoid Tumors epidemiology based on gender analyzed that Desmoid Tumors are more common in women as compared to men
• The Desmoid Tumors market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Desmoid Tumors pipeline products will significantly revolutionize the Desmoid Tumors market dynamics.

Desmoid Tumors Overview
Desmoid tumours (DT), which form in connective tissue, are benign growths. Because of their resemblance to the dangerous tumour fibrosarcoma, they are sometimes known as aggressive fibromatosis. Because it does not metastasize-or spread-to other bodily parts, it is regarded as benign.

Get a Free sample for the Desmoid Tumors Market Report
https://www.delveinsight.com/report-store/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Desmoid Tumors Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Desmoid Tumors Epidemiology Segmentation:
The Desmoid Tumors market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Desmoid Tumors
• Prevalent Cases of Desmoid Tumors by severity
• Gender-specific Prevalence of Desmoid Tumors
• Diagnosed Cases of Episodic and Chronic Desmoid Tumors

Download the report to understand which factors are driving Desmoid Tumors epidemiology trends @ Desmoid Tumors Epidemiology Forecast
https://www.delveinsight.com/sample-request/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Desmoid Tumors Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Desmoid Tumors market or expected to get launched during the study period. The analysis covers Desmoid Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Desmoid Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Desmoid Tumors Therapies and Key Companies
• Nirogacestat: SpringWorks Therapeutics
• AL102: Ayala Pharmaceuticals
• Tegavivint: Iterion Therapeutics
• Sirolimus: Pfizer
• Imatinib: Novartis
• Nab-Rapamycin: Aadi Bioscience, Inc.
• Fentanyl sublingual spray: INSYS Therapeutics Inc
• REC-4881: Recursion Pharmaceuticals Inc.

Discover more about therapies set to grab major Desmoid Tumors market share @ Desmoid Tumors Treatment Market
https://www.delveinsight.com/sample-request/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Desmoid Tumors Market Drivers
• Desmoid Tumors is a rare form of cancer; thus, companies developing treatment options for the same can possess several advantages like market exclusivities, premium pricing, subsidy for conducting trials, and several other benefits from the government bodies for R&D.

Desmoid Tumors Market Barriers
• Lack of approved therapies indicate an opportune time to invest in research and development as the Desmoid Tumors therapy segment is currently being explored by only a handful of players.

Scope of the Desmoid Tumors Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Desmoid Tumors Companies: Pfizer, Novartis, SpringWorks Therapeutics, Ayala Pharmaceuticals, Iterion Therapeutics, Aadi Bioscience, Inc., INSYS Therapeutics Inc, Recursion Pharmaceuticals Inc., and others
• Key Desmoid Tumors Therapies: Sirolimus, Imatinib, Nirogacestat, AL102, Tegavivint, Nab-Rapamycin, Fentanyl sublingual spray, REC-4881, and others
• Desmoid Tumors Therapeutic Assessment: Desmoid Tumors current marketed and Desmoid Tumors emerging therapies
• Desmoid Tumors Market Dynamics: Desmoid Tumors market drivers and Desmoid Tumors market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Desmoid Tumors Unmet Needs, KOL's views, Analyst's views, Desmoid Tumors Market Access and Reimbursement

To know more about Desmoid Tumors companies working in the treatment market, visit @ Desmoid Tumors Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/desmoid-tumors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Desmoid Tumors Market Report Introduction
2. Executive Summary for Desmoid Tumors
3. SWOT analysis of Desmoid Tumors
4. Desmoid Tumors Patient Share (%) Overview at a Glance
5. Desmoid Tumors Market Overview at a Glance
6. Desmoid Tumors Disease Background and Overview
7. Desmoid Tumors Epidemiology and Patient Population
8. Country-Specific Patient Population of Desmoid Tumors
9. Desmoid Tumors Current Treatment and Medical Practices
10. Desmoid Tumors Unmet Needs
11. Desmoid Tumors Emerging Therapies
12. Desmoid Tumors Market Outlook
13. Country-Wise Desmoid Tumors Market Analysis (2019-2032)
14. Desmoid Tumors Market Access and Reimbursement of Therapies
15. Desmoid Tumors Market Drivers
16. Desmoid Tumors Market Barriers
17. Desmoid Tumors Appendix
18. Desmoid Tumors Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports by DelveInsight

Iga Nephropathy Market
https://www.delveinsight.com/report-store/iga-nephropathy-market
DelveInsight's "IgA Nephropathy Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of the IgA Nephropathy, historical and forecasted epidemiology as well as the IgA Nephropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan, and China.
Vutrisiran Market
https://www.delveinsight.com/report-store/vutrisiran-market
DelveInsight's "Vutrisiran Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Vutrisiran, historical and forecasted epidemiology as well as the Vutrisiran market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastroesophageal Reflux Disease Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market
DelveInsight's "Gastroesophageal Reflux Disease (GERD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastroesophageal Reflux Disease (GERD), historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease (GERD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Cerebral Palsy Market
https://www.delveinsight.com/report-store/cerebral-palsy-market
DelveInsight's 'Cerebral Palsy Market Insights, Epidemiology, and Market Forecast 2032' report delivers an in-depth understanding of cerebral palsy, historical and forecasted epidemiology as well as cerebral palsy market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Granulomatosis With Polyangiitis Market
https://www.delveinsight.com/report-store/granulomatosis-with-polyangiitis-market
DelveInsight's "Granulomatosis With Polyangiitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Granulomatosis With Polyangiitis, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
DelveInsight's "Hemophilia A Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Hemophilia A, historical and forecasted epidemiology as well as the Hemophilia A market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Graft Versus Host Disease Market https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market
DelveInsight's "Graft Versus Host Disease (GvHD) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Graft Versus Host Disease, historical and forecasted epidemiology as well as the Graft Versus Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Hemorrhoids Market
https://www.delveinsight.com/report-store/hemorrhoids-market
DelveInsight's "Hemorrhoids Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hemorrhoids, historical and forecasted epidemiology as well as the Hemorrhoids market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Asthma Market
https://www.delveinsight.com/report-store/asthma-market
DelveInsight's "Asthma - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Myelodysplastic Syndrome Market
https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
DelveInsight's "Myelodysplastic Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Myelodysplastic Syndrome, historical and forecasted epidemiology as well as the Myelodysplastic Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Desmoid Tumors Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Pfizer, Novartis, SpringWorks Therapeutics, Ayala Pharmaceuticals, Iterion Therapeutics, Aadi Bioscience here

News-ID: 3459165 • Views:

More Releases from DelveInsight Business Research

Prader-Willi Syndrome Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight | Pfizer, Soleno Therapeutics, Neuren Pharmaceuticals, Harmony Biosciences, Gedeon Richter Plc, Montefiore Medical Center
Prader-Willi Syndrome Market to Witness Upsurge in Growth During the Forecast Pe …
DelveInsight's "Prader-Willi Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Prader-Willi Syndrome, historical and forecasted epidemiology as well as the Prader-Willi Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Prader-Willi Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prader-Willi Syndrome Market Forecast https://www.delveinsight.com/sample-request/prader-willi-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Overactive Bladder Market and Epidemiology 2034: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Urovant Sciences, Bayer, Taiho Pharmaceuticals, AbbVie, Medytox, Velicept Therapeutics, Sumitovant Biopharm
Overactive Bladder Market and Epidemiology 2034: Treatment Market, Therapies, Co …
The Overactive Bladder Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Overactive Bladder Syndrome pipeline products will significantly revolutionize the Overactive Bladder Syndrome market dynamics. DelveInsight's "Overactive Bladder Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Overactive Bladder Syndrome, historical and forecasted epidemiology as well as the Overactive Bladder
GM2 Gangliosidosis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2024-2034), Analyzes DelveInsight | Azafaros A.G., IntraBio, Children's National Research Institute, Sanofi
GM2 Gangliosidosis Market is Predicted to Exhibit Remarkable Growth During the F …
DelveInsight's "GM2 Gangliosidosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the GM2 Gangliosidosis, historical and forecasted epidemiology as well as the GM2 Gangliosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the
Friedreich's Ataxia Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | Reata Pharma, Retrotope, PTC Therapeutics, Minoryx Therapeutics
Friedreich's Ataxia Market to Observe Impressive Growth During the Forecast Peri …
The Friedreich's Ataxia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Friedreich's Ataxia pipeline products will significantly revolutionize Friedreich's Ataxia market dynamics. DelveInsight's "Friedreich's Ataxia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Friedreich's Ataxia, historical and forecasted epidemiology as well as the Friedreich's Ataxia market trends in the United States,

All 5 Releases


More Releases for Desmoid

Desmoid Tumor Treatment Market by Market Trends, Active Modernization in Technol …
It is an objective of every organization to achieve the set profit goals and this Desmoid Tumor Treatment market report helps key players in this regard by providing finest market tactics as well as enable them to attain larger revenues in the business. Measuring present success level is also easy with the help of this market report. Functional areas of business are covered here. Business tactics provided here will
Desmoid Tumor Market Size 2021 | Incredible Possibilities of Growth and Opportun …
Desmoid tumor, also called aggressive fibromatosis, often occurs in the legs, arms, and abdomen. These tumors are noncancerous growths that occur in the human connective tissue. Since these tumors are noncancerous, they do not spread to other body parts; however, they can be aggressive and grow into nearby organs and structures. The common symptoms associated with desmoid tumors include an area or mass of swelling, loss of function in that
Desmoid Tumor Market Growing Dynamically with Leading Top Key Players like Amgen …
Desmoid tumor, also called aggressive fibromatosis, often occurs in the legs, arms, and abdomen. These tumors are noncancerous growths that occur in the human connective tissue. Since these tumors are noncancerous, they do not spread to other body parts; however, they can be aggressive and grow into nearby organs and structures. The common symptoms associated with desmoid tumors include an area or mass of swelling, loss of function in that
Desmoid Tumors Market to show vigorous growth with industry’s leading players …
Desmoid Tumors Market Top Key Players Some of key the players in the market are Amgen Inc., Novartis AG, Abbott Laboratories, Bayer AG, AbbVie Inc., Beckman Coulter Inc., Stryker Corporation, Debiopharm Group, F. Hoffmann-La Roche Ltd, and others. Market Scenario Desmoid tumors are also known as desmoid fibromatosis. These benign growths occur very rarely in the general population. Desmoid tumor usually develops in the fibrous tissue of the body, commonly in the
Desmoid Tumors Market Market Overview, Leading Players-Amgen Inc., Novartis AG, …
Market Scenario Desmoid tumors are also known as desmoid fibromatosis. These benign growths occur very rarely in the general population. Desmoid tumor usually develops in the fibrous tissue of the body, commonly in the arms, legs or midsection, and sometimes in the head and neck. The term desmoid was derived from the Greek word desmos, which means tendonlike. Desmoid tumors appear as well-differentiated, and firm overgrowths of fibrous tissue. According to
Global Desmoid Tumors Market 2018 Major Key Companies – Beckman Coulter Inc., …
Market Scenario Desmoid tumors are also known as desmoid fibromatosis. These benign growths occur very rarely in the general population. Desmoid tumor usually develops in the fibrous tissue of the body, commonly in the arms, legs or midsection, and sometimes in the head and neck. The term desmoid was derived from the Greek word desmos, which means tendonlike. Desmoid tumors appear as well-differentiated, and firm overgrowths of fibrous tissue. According to